Aerosolized iloprost as a bridge to lung transplantation in a patient with cystic fibrosis and pulmonary hypertension.
We describe a patient with cystic fibrosis, end-stage lung disease, and secondary pulmonary hypertension in whom aerosolized iloprost was effective in lowering pulmonary artery pressure and improving functional status, thus proving successful as a bridge to lung transplantation. Inhaled iloprost may be an efficient and selective approach to treat pulmonary hypertension related to end-stage obstructive pulmonary disease.
Tissières
Pierre
P
Unit of Pediatric Cardiology, University Children's Hospital, Geneva, Switzerland.
Nicod
Laurent
L
Barazzone-Argiroffo
Constance
C
Rimensberger
Peter C
PC
Beghetti
Maurice
M
D000280:Administration, Inhalation; D000328:Adult; D003550:Cystic Fibrosis / Q000150:complications*; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications* / Q000188:drug therapy; D016285:Iloprost / Q000008:administration & dosage*; D016040:Lung Transplantation / Q000379:methods*; D009569:Nitric Oxide / Q000008:administration & dosage; D011292:Premedication; D012131:Respiratory Insufficiency / Q000209:etiology / Q000601:surgery*; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents / Q000008:administration & dosage*
D014665:Vasodilator Agents; D009569:Nitric Oxide; D016285:Iloprost